EMA’s AI Principles Intended To Be ‘Flexible & Long Lasting’

There is “a lot of flexibility” in the European Medicines Agency’s reflection paper on the use of artificial intelligence during drug development, which is principles-driven rather than setting rigid recommendations, says the agency’s Florian Lasch.

Florian Lasch speaking at the TOPRA Symposium 2024 • Source: Pink Sheet

The European Medicines Agency recently finalized a reflection paper on the use of artificial intelligence (AI) during the lifecycle of medicinal products to help manufacturers use AI in a safe and effective way.

The approach taken by the EMA is a flexible one that is “focused on principles, rather than on specific recommendations,”...